BRD4 and neoplasm: It was shown that the type of NUTM1 fusion expressed may be one of the factors that contribute to iBET sensitivity, with NC tumor cells expressing the BRD4-NUTM1 ex11:ex2 fusion being on average more than tenfold more sensitive to iBET treatment than cells with BRD4-NUTM1 ex15:ex2 or ex14:ex2 fusions [39].